The Chart of the Day belongs to Acorda Therapeutics (ACOR). I found the stock by sorting the All Time High list for the stock with the best technical buy signals, then used the Flipchart feature to review the charts.
Acorda Therapeutics is commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda currently markets Zanaflex Capsules for the management of spasticity. The Company's lead product candidate, Fampridine-SR, for the improvement of walking ability in persons with multiple sclerosis. It develops therapies that restore neurological function to people with spinal cord injury, multiple sclerosis and related conditions of the nervous system.
Barchart's Opinion trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com web site when you read this report.
Barchart technical indicators:
- 100% Barchart technical buy signals
- Trend Spotter buy signal
- Above its 20, 50 and 100 day moving averages
- 12 new highs and up 11.08% in the last month
- Relative Strength Index 67.01%
- Barchart computes a technical support level at 39.37
- Recently trade at 41.82 with a 50 day moving average of 37.23
Fundamental factors:
- Market Cap $1.75 billion
- P/E 49.83
- Revenue expected to grow 14.70% this year and another 7.00% next year
- Earnings estimated to increase 17.90% this year, be down next year but compound at an annual rate of 45.00% for the next 5 years
- Wall Street analysts issued 2 strong buy, 3 buy and 7 hold recommendations on the stock
The 50-100 Day MACD Oscillator has been an effective technical trading strategy on this stock and should be used to find an exit point.
No comments:
Post a Comment